PDUFA V focus on speedy approval of new drugs by US FDA is misguided, suggests study - UPDATE
This article was originally published in SRA
The US Food and Drug Administration faces constant criticism from the pharmaceutical industry for being too slow with drug approvals but a new study shows that the FDA has in fact been faster than its counterparts in the EU and Canada at approving novel therapeutics over the last decade1.
You may also be interested in...
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.